TGTX

Several events have impacted TG Therapeutics' stock price in the past six months. In Q1 2026, the company reported earnings per share (EPS) of $0.12, missing the consensus estimate, but revenue reached $204.92 million, surpassing analyst estimates, and subsequently raised its full-year 2026 revenue target. The company released its Q4 2025 earnings on February 26, 2026, reporting an EPS of $0.14. Enrollment was completed in a Phase 3 trial for a subcutaneous formulation of BRIUMVI and the Phase 3B ENHANCE trial for intravenous (IV) BRIUMVI. TG Therapeutics refinanced an existing $250 million facility and secured a new five-year, $750 million term loan, resulting in $500 million in net cash and increasing its pro forma cash to approximately $700 million without equity dilution, and expanded its share buyback plans to $300 million. Analysts have issued various ratings and price target revisions, and the stock has seen a 17% increase since January, outperforming the S&P 500.